Purdue Pharma Appoints Margaret K. Feltz as Chief Ethics & Compliance Officer; Bert Weinstein Retires

Feltz will also serve as an Executive Committee member

STAMFORD, Conn., Feb. 7, 2017 – Purdue Pharma L.P. today announced the appointment of Margaret K. Feltz, Esq. to Vice President and Chief Ethics & Compliance Officer, reporting to President and Chief Executive Officer Mark Timney. Feltz succeeds Bert Weinstein, Esq., who retired from Purdue Pharma in December 2016. In this role, Feltz is responsible for the Company’s overall ethics and compliance strategy and leadership, technical direction and guidance concerning Purdue business activities, decisions and operations. Feltz will also serve as a member of the Purdue Pharma’s Executive Committee.

“At a time of transformation for Purdue, it is critical we maintain our commitment to the highest ethical standards and continued compliance with all laws, regulations and company policies,” said Mark Timney, President and Chief Executive Officer, Purdue Pharma L.P. “Maggie is an excellent choice to help us achieve these goals.”

Feltz began her career with Purdue Pharma in 2004, as a Senior Manager in the company’s compliance program. Prior to joining Purdue Pharma, Feltz worked as a healthcare attorney at McDermott, Will & Emery and later as Compliance Counsel for Boehringer Ingelheim Pharmaceuticals, Inc. Feltz was a long-standing co-chair and remains an active member of the Pharmaceutical Compliance Forum, a leading industry group representing nearly 60 research-based pharmaceutical manufacturers and supporting best practices sharing in pharmaceutical ethics and compliance.

Feltz received her Juris Doctor degree, cum laude, from Case Western Reserve University School of Law and her Master of Arts degree in Bioethics, magna cum laude, from Case Western Reserve University School of Medicine. Feltz earned a Bachelor of Arts degree from Wellesley College, where she majored in bioethics with a concentration in biology.

Bert Weinstein, Esq. served as Purdue Pharma’s Chief Ethics & Compliance Officer since 2004.

“Both as an individual leader and industry expert, Bert has had a profound impact on the field of pharmaceutical compliance,” said Timney. “Under his leadership, Purdue built industry-leading compliance strategies, programs and a corporate culture that has increased compliance awareness and reduced regulatory risk.”

ABOUT PURDUE PHARMA L.P.

Purdue Pharma is a privately-held pharmaceutical company and is part of a global network of independent associated companies that is known for pioneering research in chronic pain and opioids with abuse deterrent properties. The company’s leadership and employees are committed to providing healthcare professionals, patients and caregivers quality products and educational resources to support their proper use. Purdue Pharma is engaged in the development, production and distribution of both prescription and over-the-counter medicines and hospital products. With Purdue Pharma’s expertise in drug development, commercialization and life-cycle management, the company is diversifying in high-need areas to expand through strategic acquisitions and creative partnerships. For more information, please visit www.purduepharma.com.

# # #

Media Inquiries:
Catherine London
Corporate Communications
Purdue Pharma L.P.
203-588-7530
catherine.london@pharma.com

The prescription and illicit opioid abuse crisis is a multifaceted public health challenge, and as a manufacturer of prescription opioids, we have a responsibility to join the fight. At Purdue we are committed to lead our industry in helping address our nation's prescription and illicit opioid abuse crisis.

There is more to come – as we continue to work with partners and experts to deliver solutions. Below you will find additional information about our efforts.

Read our open letter about the opioid crisis.